Eris Lifesciences Ltd (NSE:ERIS)
₹ 1042.9 11.1 (1.08%) Market Cap: 141.66 Bil Enterprise Value: 155.44 Bil PE Ratio: 36.17 PB Ratio: 5.48 GF Score: 97/100

Q2 2024 Eris Lifesciences Ltd Earnings Call Transcript

Nov 08, 2023 / 11:30AM GMT
Release Date Price: ₹897.8 (+3.30%)
Operator

Ladies and gentlemen, good day, and welcome to Q2 and H1 FY '24 Earnings Conference Call of Eris Lifesciences Limited. We have with us on the call today Mr. Amit Bakshi, Chairman and Managing Director; and Mr. V. Krishnakumar, Chief Operating Officer and Executive Director. (Operator Instructions) Please note that this conference is being recorded.

I now hand the conference over to Mr. V. Krishnakumar, Chief Operating Officer and Executive Director of the company. Thank you, and over to you, sir.

Krishnakumar Vaidyanathan
Eris Lifesciences Limited - Executive Director & COO

Thank you. Good afternoon, and welcome to our conference call for second quarter of FY '24. Earlier today, we have announced the execution of definitive agreement for the acquisition of Biocon's Nephrology and Dermatology businesses for a consideration of INR 366 crores, inclusive of working capital that will be conveyed to us as part of the business. This business is currently operating at a revenue run rate of INR 100 crores per annum. The key leadership and entire field

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot